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Engagement of the CD3/T cell antigen receptor complex on small, resting T cells is insufficient 
to trigger cell-mediated cytotoxicity or to induce a proliferative response. In the present study, 
we have used genetic transfection to demonstrate that interaction of the B7-BB1 B cell activation 
antigen with the CD28  T  cell differentiation antigen costimulates cell-mediated cytotoxicity 
and proliferation initiated by either anti-CD2 or anti-CD3 monoclonal antibody (mAb). Moreover, 
a B7-negative Burkitt's lymphoma cell line that fails to stimulate an allogeneic mixed lymphocyte 
response is rendered a potent stimulator after transfection with B7. The mixed leukocyte reaction 
proliferative response against the B7 transfectant is inhibited by either anti-CD28 or B7 mAb. 
We also demonstrate that freshly isolated small, resting human T  cells can mediate anti-CD3 
or anti-CD2  mAb-redirected cytotoxicity against a murine Fc receptor-bearing  mastocytoma 
transfected with human B7. These preexisting cytotoxic T lymphocytes in peripheral blood are 
present  in  both  the  CD4  and  CD8  subsets,  but  are  preferentially  within  the  CD45RO + 
"memory" population. While small, resting T cells apparently require costimulation by CD28/B7 
interactions, this requirement is lost after T cell activation. Anti-CD3 initiates a cytotoxic response 
mediated by in vitro cultured T cell clones in the absence of B7 ligand. The existence of functional 
cytolytic T cells in the small, resting T cell population may be advantageous in facilitating rapid 
responses to immune challenge. 
T  lymphocytes recognize antigen via the CD3/TCR com- 
plex. Binding of anti-CD3 or anti-TCR mAb to T cells 
results  in  a  rapid  increase  in  intracellular  [Ca 2+]  and  the 
generation  of inositol  triphosphate  (IP3)  (1-4).  Although 
crosslinking of CD3/TCR alone is often sufficient to induce 
inositolphosphate pathway activation, other signals are ap- 
parently necessary to induce functions such as cytokine secre- 
tion and proliferation (4).  Both soluble factors and interac- 
tion  with  cell  surface  receptors  have  been  implicated  as 
costimulators of CD3/TCR-mediated activation. For example, 
allo-antigen-specific helper T  cells fail to produce cytokines 
in response to HLA-DR7 antigen expressed in murine L cells. 
However, cotransfection of HLA-DR7 and CD54 (intracellular 
adhesion molecule I [ICAM-1]), a cellular ligand for CDll/18 
leukocyte function-associated molecule 1 [LFA-1]), restores T 
cell responsiveness (5). Thus, antigen-specific recognition alone 
may be insufficient to trigger effector functions since addi- 
tional accessory molecules are required for an efficient response. 
CD28 is a disulfide-linked homodimer that is expressed 
on the majority of human peripheral blood T  cells (6,  7). 
mAbs against CD28 in conjunction with phorbol ester in- 
duce T  cell proliferation (7)  and augment proliferation in- 
duced by anti-CD3  or anti-CD2  mAb (8-12).  Anti-CD28 
mAb-induced proliferation is IL-2 dependent (7, 8) and pos- 
sibly results from stabilization of messenger RNA for IL-2 
and other cytokines (13). 
Recently, it has been demonstrated that a B cell activation 
antigen, B7 (14) or BB1 (15),  is a natural ligand for CD28 
and that this receptor/ligand interaction mediates heterotypic 
adhesion (16).  Interaction of CD28 and B7 results in aug- 
mentation of T  cell proliferation and cytokine production, 
and antibodies against CD28 or B7 inhibit alloantigen and 
mitogen-induced proliferative responses (16, 17). B7 is weakly 
expressed on resting B cells and monocytes, and is elevated 
after stimulation with pokeweed mitogen, anti-Ig, anti-HLA 
class II, and EBV (14,  15,  17). Therefore, it is likely that T 
cell activation via CD28 will depend on the capacity of the 
APC to upregulate expression of B7. The importance of the 
CD28/B7  interaction  in  polyclonal  mitogenic  responses 
prompted us to investigate whether the binding orB7 to CD28 
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alloantigen and can augment the generation of T cell-medi- 
ated cytotoxicity in small, resting T  lymphocytes. 
Materials and Methods 
Preparation of TLyraphocytes.  Human peripheral blood was ob- 
tained from the Stanford Blood Center (Palo Alto, CA). Mononu- 
clear cells were isolated by density gradient centrifugation using 
Ficoll/Hypaque. Monocytes and B cells were depleted by plastic 
adherence and passage through nylon wool columns (18). Nonad- 
herent lymphocytes were fractionated by centrifugation on discon- 
tinuous gradients consisting of 30% and 40% Percoll (Pharmacia 
Fine Chemicals, Piscataway, NJ) in PBS containing 10% FCS (18). 
High buoyant density lymphocytes enriched for small, resting T 
cells were isolated from the bottom of the Percoll gradients. Thymo- 
cytes from 1-yr-old children undergoing cardiac surgery were ob- 
tained from Stanford Medical Center (Palo Alto, CA). The biop- 
sies were minced with scissors, the single cell suspension was passed 
through a nylon mesh, and mononudear cells were isolated by 
Ficoll/Hypaque density centrifugation. Umbilical cord blood was 
collected from healthy full-term neonates immediately after vag- 
inal delivery. High buoyant density cord blood CD3 + T lympho- 
cytes were obtained as for peripheral  blood. 
T Cell Clones.  T cell clones were established from normal PBL 
or fetal liver, as described (19). The following dones were used: 
D75b2.22 is a TCR-'y/6 § CTL clone established from fetal liver; 
D60b.1  and 1320.3 are TCR-c~/~ + CTL clones established from 
fetal liver. Jp28a.6  is a TCR-cx/B § CTL done established from 
normal PBL. Antigen spedtlcity of these T cell clones has not been 
determined. 
mAbs.  BB1 mAb (15) was generously provided by Dr. Ed Clark 
(University of Washington, Seattle, WA). L293 is a murine IgG1 
mAb directed  against CD28 that was generated by immunizing 
BALB/c mice with the HPB-ALL T cell line and fusing immune 
splenocytes with Sp2/0 myeloma cells. L303 (IgG2a, g) and L304 
(IgG1, g) are murine mAbs directed against CD2 and CD2R, respec- 
tively, that were generated by immunizing BALB/c mice with anti- 
CD3-activated PBL and fusing immune splenocytes with Sp2/0 
myeloma cells. Other mAbs were generously provided by Becton 
Dickinson  Immunocytometry Systems  (San Jose,  CA).  F(ab')2 
fragments of anti-CD3, CD28 and CD16 mAbs (all IgG1 isotype) 
were prepared  using immobilized pepsin  (Pierce Chemical Co., 
Rockford, IL). Purity of F(ab')2 fragments was verified by SDS- 
PAGE analysis. 
Transfection.  P815,  a murine mastocytoma cell line, and Ramos, 
a human Burkitt's lymphoma cell line, were obtained from Amer- 
ican Type Culture Collection (Rockville, MD). Human B7 cDNA 
(generously provided by Dr. J. Allison, University of California, 
Berkeley) was subcloned into the pBJ expression vector (20). 107 
P815 and Ramos cells were transfected with 15 #g pBJ/B7 plasmid 
by electroporation  (2.0 KV, 25/tFD) using a Gene Pulser (Bio-Rad 
Laboratories,  Richmond, CA)  and  selected in culture medium 
(ILPMI 1640 [M. A. Bioproducts,  Walkersville, MD] +  10% FCS 
[JR Scientific, Woodland, CA],  1 mM sodium pyruvate,  1 mM 
L-glutamine,  1%  penicillin-streptomycin)  supplemented  with 2 
mg/ml G418 (Gibco Laboratories, Grand Island, NY). After drug 
selection,  B7-transfected  P815 and Ramos cells were cloned and 
selected for high cell surface B7 expression by flow cytometry. Trans- 
fectants were maintained in culture medium containing 1 mg/ml 
G418. 
Anti-CD3-induced Redirected Cytotoxicity Assays.  Cytotoxicity 
was measured in a 4-h S~Cr-release assay (18). Anti-CD3 or anti- 
CD2 mAbs were added to SlCr-labeled P815 or B7 § P815 target 
cells 30 min before addition of effector T cells, unless indicated 
otherwise. In mAb blocking studies, all mAbs were used at a final 
concentration of 5 #g/ml and were added at initiation of the assay. 
Proliferation Assays.  Irradiated  (80 Gy) P815 and B7 § P815 (3 
x  104  cells/well)  were  plated  with  anti-CD3  (anti-Leu-4;  5 
/tg/ml) or anti-CD2 (L303 and L304,  1.25 #g/ml) mAbs in flat- 
bottomed 96-well microtiter plates (Falcon Labware, Lincoln Park, 
NJ). After incubation for 30 min at room temperature, high buoyant 
density T  cells were added at  105 cells/well.  Cultures were in- 
cubated at 37~  with 5% CO2 in a humidified atmosphere for 
72 h. For the mixed lymphocyte response, 105 high buoyant den- 
sity T cells and 104 irradiated (80 Gy) Ramos or B7" Ramos cells 
were added to microtiter plate wells with or without mAbs and 
were incubated for 7 d. All cultures were labeled for the final 18 h 
with 1/~Ci/well [3H]thymidine (New England Nuclear, Boston, 
MA) and were harvested on a 96-well plate harvester (LKB Instru- 
ments Inc., Gaithersburg, MD). Incorporated radioactivity was mea- 
sured in a beta plate scintillation counter (LKB Instruments, Inc.). 
Each value is the mean of triplicate wells. Standard mean error of 
the triplicates  was <10%. 
lmraunofluorescence and Flow Cytoraetry.  Methods of immuno- 
fluorescence and flow cytometry have been described previously 
(21, 22).  Flow cytometry was performed using a FACScan  |  or 
FACStar  Pgus~ (Becton Dickinson Immunocytometry Systems). 
Results and Discussion 
CD28/B7 Costiraulates Both CD2- and CD3-dependent T Cell 
Proliferation.  Human B7 cDNA (23) was subcloned into a 
mammalian expression vector, transfected into an FcR-bearing 
murine mastocytoma cell line, P815, and stable transfectants 
expressing high levels of surface B7 were established. A rep- 
resentative  transfectant is  shown  in  Fig.  1.  To  determine 
whether the B7 + P815 cells were functionally competent to 
activate CD28, purified high buoyant density peripheral blood 
T  cells were cocultured with irradiated B7 + P815 or parental 
P815 cells in the presence or absence of anti-CD3 mAb. Con- 
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Figure 1.  B7 + P815 transfectants.  Parental P815 (.,4) and B7 + P815 (B) 
transfectants were stained  with control or BB1 mAb, followed  by FITC- 
conjugated goat anti-mouse Ig. Samples were analyzed  by flow cytom- 
etry. The x-axis represents fluorescence (four-decade log scale) and the 
y-axis represents the relative cell number. Histograms from cells stained 
with control mAb (nearest the ordinate) are superimposed  over the histo- 
gram of cells stained with BB1. 
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Figure 2.  B7 costimulation of anti-CD3-induced T cell proliferation.  (A) Proliferation of small, resting peripheral blood T cells cocultured with 
irradiated P815 (e) or B7 + P815 (.)  in the presence of anti-CD3 mAb. (B) BB1 mAb, but not IgM control mAb Leu-7, inhibits B7 + P815 augmen- 
tation of anti-CD3-induced T cell proliferation.  Note that BB1 mAb is a murine IgM and does not interfere with binding of anti-CD3 mAb to IgG 
Fc receptors on I)815. (C) Intact but not F(ab')2 fragments of anti-CD3 mAb stimulate proliferation of small, resting T cells in the presence of B7 + P815. 
sistent with prior findings (24), freshly isolated,  small pe- 
ripheral blood T cells obtained from high buoyant density 
lymphocytes were minimally responsive to triggering via anti- 
CD3. However, when T cells were stimulated by coculture 
with B7 + P815, but not parental P815, we observed a pro- 
nounced effect on anti-CD3-induced proliferation (Fig. 2 A). 
Anti-CD3-induced proliferation costimulated by B7 + P815 
was substantiaUy inhibited by anti-B7 mAb BB1 (IgM) but  A 
not isotype-matched  antioCD57  mAb Leu-7 (IgM)  (Fig.  2  RAaOS  (4 
B).  Similarly, the addition of anti-CD28 F(ab')2 fragments 
resuhed in the inhibition of T cell proliferation (not shown).  .7-RAaOS  (-) 
This indicated that the response was  dependent  upon the 
CD28/B7 interaction. Anti-CD3-induced proliferation was  eT-aAaOS  eel 
Fc dependent,  in that no proliferation was observed when  .7.~.os  ~.-~ n 
T ceUs and B7 + P815 were cultured with F(ab')~ anti-CD3 
fragments  (Fig.  2 C).  B7-RAMOSfI'lbCD28Fab'2 
mAbs directed against certain CD2 epitopes induce T cell 
proliferation (25).  To determine whether the CD28/B7 in-  B7-aAaOS=tbCO16Fab'2 
teraction could also stimulate T cell proliferation triggered  n 
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Figure 3.  B7 costimulation of anti-CD2-induced T cell proliferation. 
Small, resting peripheral blood T cells were cocuhured with irradiated 
parental P815 (Ill), B7+  P815 (II), or without P815 cells ([~)  in the 
presence or absence of anti-CD3, anti-CD2 (L303), and/or anti-CD2g 
(L304) mAb. 
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via CD2, we examined the effect of anti-CD2 mAbs on B7- 
dependent T cell proliferation (Fig. 3). Saturating concen- 
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Figure 4.  B7 expression  augments an allogeneic MLR. Small, resting 
peripheral blood T cells from two donors (A and B) were cocultured with 
irradiated Ramos or B7 + Ramos in the presence or absence of BB1 mAb, 
anti-CD28 F(ab')2 fragments,  control IgM mAb Leu-7, or control anti- 
CD16 F(ab')2 fragments,  as indicated. the presence of P815.  However, when resting T  cells were 
costimulated with B7 § P815,  L303 and L304 together in- 
duced significant proliferation, which was inhibited by BB1 
mAb (not shown). These results suggest that the binding 
of B7 to CD28 costimulates both the CD3 and CD2 activa- 
tion pathways. 
CD28/B7 Interactions Augment Primary Allogeneic MLR. 
EBV-transformed B cell lines are known to serve as potent 
stimulators of alloantigen-induced T cell proliferation. B lym- 
phoblastoid cell lines have been reported to express high levels 
of call surface B7 (15), suggesting the possibility that B7 ex- 
pression is necessary for the generation of a primary MLR. 
Ramos is an EBV-negative American Burkitt's lymphoma cell 
line that expresses high levels of class I and II MHC antigens, 
but does not express B7. Preliminary experiments demon- 
strated that this cell line was a poor stimulator of allogeneic 
MLR.  Ramos was transfected with B7 cDNA, and stable 
transfectants expressing high levels of B7 were selected. Fig. 4 
shows the proliferative response of small, resting T cells from 
two donors cocuhured with irradiated parental Ramos and 
B7-transfected Ramos. Parental B7-negative Ramos failed to 
stimulate small, resting T  cells. By contrast, small, resting 
T cells cocultured with B7-transfected Ramos mediated sub- 
stantial proliferative responses.  These proliferative responses 
were substantially inhibited by  either BB1  or  anti-CD28 
F(ab')2 fragments, but  not isotype-matched anti-CD57  or 
anti-CD16  F(ab')2 fragments. 
CD28/B7 Interactions  Augment CeU-mediated  Cytotoacicity Trig- 
gered through CD3 and CD2.  CTL clones can lyse Fc receptor- 
bearing targets in the presence of anti-CD3 mAb in a "re- 
directed" cytotoxicity assay (26-29).  Unlike CTL  clones, 
freshly isolated small resting T lymphocytes do not mediate 
anti-CD3 redirected lysis (29, 30), although a small subset 
of CD56 § or CD57 + T cells that may represent in vivo ac- 
tivated T cells do mediate this function (30,  31). Thus, en- 
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plates with titered amount of anti- 
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peripheral  blood  T  calls  were 
added and the assay was harvested 
after 4  h.  Results  from experi- 
ments using two different T  call 
donors (A and B) are shown. E/T 
ratio was 20:1. 
gagement of CD3/TCK alone is insufficient to trigger a cyto- 
lytic response in the majority of resting peripheral blood T 
lymphocytes. It is possible that small, resting T lymphocytes 
lack the cellular machinery necessary for cytotoxicity. Alter- 
natively, additional signals  may be necessary to generate a 
cytolytic response in resting T cells that are not required for 
stimulation of activated T cells. The ability of combinations 
of hetero-bifunctional anti-CD3/antitumor and anti-CD28/ 
antitumor mAbs to induce cytotoxicity suggested that inter- 
action of CD28 with its natural ligand may provide the re- 
quired costimulatory signal for generation of CTL from resting 
peripheral blood T  cells (32).  As shown in Fig.  5,  freshly 
isolated small resting peripheral blood T cells demonstrated 
potent anti-CD3-redirected cytotoxicity against B7 + P815, 
but not parental P815,  detectable using a 4-h 5~Cr release 
assay. Comparable results were obtained using three indepen- 
dently derived B7 + P815 transfectants; however, P815 trans- 
fectants expressing high levels of CD16-II were not lysed in 
the presence of anti-CD3  (not shown). Lysis of B7 + P815 
transfectants was  inhibited by BB1  or  anti-CD28  P(ab')2 
fragments (Fig.  6 A). Anti-CD3-induced cytotoxicity was 
Fc  dependent  since anti-CD3  F(ab')2  fragments failed  to 
trigger lysis against B7 + P815  (Fig.  6 B). 
mAbs against CD4 (Leu-3a), CD5 (Leu-1), CD7 (Leu-9), 
CD8 (Leu-2a),  CDlla (L7), CD18 (L130), and CD38 (Leu- 
17) failed to induce redirected lysis against parental or B7 + 
P815 cells (not shown). However, as with the proliferative 
response, appropriate combinations of anti-CD2 mAb (L303 
+  L304) could trigger cytotoxicity against B7 + P815, but 
not parental P815 (Fig.  7). Anti-CD2-induced cytotoxicity 
was inhibited by BB1 antibody, but not isotype-matched con- 
trol mAb (not shown). These data indicate that binding of 
B7 to CD28 costimulates CD3/TCR- and CD2-dependent 
T  cell-mediated cytotoxicity and demonstrates that small, 
resting T  cells are capable of cytotoxic function. 
The mechanism whereby expression of B7 on the target 
cell enables small, resting T cells to initiate lysis has not been 
defined. It is possible that the CD28/B7 interaction increases 
or stabilizes heterotypic cellular adhesion between the effector 
and target cells. However, in the present experimental system 
this seems unlikely since effectors and Fc receptor-bearing 
targets are already efficiently bridged by anti-CD3 or anti- 
CD2 mAbs. No obvious differences were observed in con- 
jugate formation between parental or B7 + P815  cells and 
effector T  cells in the presence of anti-CD3 mAb (unpub- 
lished observation). Alternatively, interaction of CD28 with 
B7 on the target may provide a cosignal to the T  cell that 
is necessary to mobilize the cellular machinery necessary for 
cytotoxicity. Preliminary studies have indicated that cytotox- 
icity is unlikely to be mediated by a soluble cytotoxic factor, 
since no bystander cytotoxicity was observed when SlCr-la- 
beled parental P815 cells were admixed with unlabeled B7 + 
P815 cells in the presence of effector T  cells and anti-CD3 
mAb (unpublished observation).  Further studies will be neces- 
sary to elucidate the mechanism of cell-mediated cytotoxicity 
initiated by small, resting peripheral blood T  cells. 
Effectors of CD28/BT-dependent Cytotoxicity.  Using B7 § 
P815 targets, anti-CD3-redirected cytotoxicity could also be 
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Figure  6.  Inhibition of B7-dependent  anti-CD3- 
redirected cytotoxicity.  (A) Anti-CD28 F(ab')z frag- 
ments and BB1 (IgM) mAb, but not control anti-CD16 
F(ab')2 fragments  or control Leu-7 (IgM)  mAbs, in- 
hibit anti-CD3-redirected  cytotoxicity  against  B7 + 
P815.  E/T ratio was 20:1.  (B)  Intact  (O),  but not 
F(ab')2 (O) anti-CD3, induces redirected cytotoxidty 
against 51Cr-labded B7 + P815 targets. (A) Cytotox- 
icity against  B7 + P815 cells  in the absence of anti- 
CD3 mAb. All mAbs were used at a final concentra- 
tion of 5 #g/ml and were added at the start of the assay. 
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Figure  7.  B7-dependent  anti-CD2-redirected  cytotoxicity.  Anti-CD2 
mAb-redirected  cytotoxicity mediated by small, resting peripheral blood 
T calls against I)815 (I) or B7 + P815 (11).  All mAbs were used at a final 
concentration  of 5 #g/ml and were added at the start of the assay. E/T 
ratio was  20:1. 
demonstrated using freshly isolated thymocyte and cord blood 
T  cell effectors,  although the activity was lower than that 
observed using adult small, resting T cells (Fig. 8 A). Both 
small resting peripheral blood CD56- ,CD4 + and CD56-, 
CD8 + T  cells  mediated equivalent  levels  of anti-CD3-in- 
duced cytotoxicity (Fig.  8 B). The ability of both CD4 and 
CD8 T  calls to mediate cytotoxicity is consistent with the 
ability of both CD4 and CD8 T cell clones to mediate anti- 
CD3-redirected  cytotoxidty, demonstrating that both major 
subsets of T lymphocytes possess the necessary cellular com- 
ponents for cytolytic function (27,  33,  34). 
Prior studies have indicated  that differential immune re- 
sponses can be mediated by subsets of T calls distinguished 
based on expression  of CD45  isoforms (35,  36).  "Virgin" 
or "naive" T cells are characterized by expression of high levels 
of CD45RA and the absence of CIM5KO, whereas "memory" 
T cells express CD45KO and lower levels of CD45RA. When 
small, resting peripheral blood T lymphocytes were separated 
into CD45KO-  and CD45KO + fractions,  CD45KO + T 
cells demonstrated a siguificantly higher level of cytotoxicity 
against B7 + P815 targets when stimulated with either anti- 
CD3 (Fig. 9) or anti-CD2 mAbs (not shown). Comparable 
results were obtained using T cells isolated from four different 
individuals. It is likely that the BT-costimulated anti-CD3-re- 
directed killing observed in cord blood T cells is accounted for 
by the presence of a low number of CD45KO + cells (9%) 
in this population. As shown in Fig.  10, both CD45RO- 
and CD45KO + T  ceUs express CD28 on the cell surface, 
demonstrating  that  this differential  responsiveness  cannot 
be  explained  simply by  lack  of CD28  expression  in  the 
CD45RO-  T  cell  population. 
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Figure  8.  T  subsets  demonstrating  B7-dependent  T 
cell-mediated cytotoxicity.  (.4) Cytotoxicity mediated by 
thymocytes,  cord blood T cells, and adult small, resting 
peripheral blood T  cells against  B7 §  P815 in the pres- 
ence  (11)  or absence (m) of anti-CD3.  Note that high 
buoyant density cord blood CD3 + T lymphocytes were 
87% CD4 + , 12% CD8 + , and 9% CD45RO + . T cells 
failed to demonstrate any cytotoxidty  against parental I>815 
in the presence of anti-CD3 mAb (not shown). (B) Anti- 
CD3-redirected  cytotoxicity  mediated  by  CD4-  and 
CD8-  small,  resting  peripheral  blood  T  cells  against 
P815  (U)  or B7 +  I)815 (m).  High buoyant  density T 
lymphocytes were stained with PE-conjugated  anti-Leu- 
19 (CD56) and FITC-conjugated anti-Leu-2 (CD8) or anti- 
Leu-3  (CD4)  mAbs.  CD8+,CD56-;  CD8-,CD56-; 
CD4 + ,CD56-, and CD4-,CD56-  subsets were isolated 
to  >95%  purity by flow cytometry.  Data are presented  for  the CD4-,CD56-  (i.e.,  CD8 +) T  cell fraction  and  the CDS-,CD56-  (i.e.,  CD4 +) 
T cell fraction.  Positively  sorted CD8 + ,CD56-  and CD4 + ,CD56-  T cells were also tested and demonstrated  equivalent cytotoxicity against B7-P815 
targets  in the presence of anti-CD3 (not shown).  E/T ratio was 20:1. 
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Figure 9.  B7-dependent cytotoxicity mediated by memory T cells. High 
buoyant density T lymphocytes  from two individuals  (A and B) were stained 
with PE-conjugated anti-CD45RO (UCHL-1) and were sorted by flow 
cytometry. Purity of the sorted subsets was >98%. Unseparated T cells 
(e), CD45RO- T cells (ll), and CD45R.O + T cells (A) were assayed 
for anti-CD3-redirected cytotoxicity against 51Cr-labeled B7 § P815 cells. 
Staining  with anti-CD45RO mAb did not affect levels of anti-CD3- 
redirected lysis compared with unstained cells (not shown). 
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Figure 10.  Coexpression  of CD28 on CD45RO-  and CD45RO § 
small, resting peripheral blood T cells. High buoyant density T lympho- 
cytes were stained with FITC-conjugated anti-CD28 (9.3), PE-conjugated 
anti-CD45RO, and PerCP-conjugated anti-CD3, or appropriate control 
mAb. Samples were analyzed on a FACScan  |  Markers were positioned 
to include >98% of cells stained with FITC- and PE-conjugated isotype 
control antibodies in the lower left quadrant (not shown). An electronic 
gate was set on PerCP-stained CD3 + T cells, and correlated fluorescence 
of FITC (CD28)  and PE (CD45RO) were displayed as a contour map 
(four-decade log scales). Analysis of CD45RO expression in small, resting 
T  cells isolated from four individuals revealed that the proportion of 
CD45R.O + T cells ranged from 48 to 78%. 
memory T  cell population is primarily responsible for this 
activity and both CD4 and CD8 T  cells are capable of this 
function. It is unlikely that this cytotoxicity is mediated by 
in vivo activated T lymphocytes, since highly purified, small, 
B7-independent Cytotoxicity Mediated by T Cell Clones.  The 
above  results  suggest  that  small,  resting  T  ceils  require 
CD28/B7 costimulation to induce CD2- or CD3-dependent 
cell-mediated cytotoxicity. In accordance with prior obser- 
vations  (26-29),  TCR-ot/[3 + and TCR-3'/5 +  CTL  clones 
mediated anti-CD3-redirected cytotoxicity against parental 
P815 (Fig. 11). Thus, while resting T cells apparently require 
CD28/B7 interactions to trigger cell-mediated cytotoxicity, 
this is no longer essential for stimulation of activated T lym- 
phocytes. However, even with the T  cell clones, we consis- 
tently observed that the presence orB7 on P815 slightly aug- 
mented cytotoxicity compared with  parental  P815  targets 
(Fig.  11). 
In summary, interaction of CD28 with its natural ligand 
B7 costimulates the induction of cell-mediated cytotoxicity, 
as well as proliferation, of small, resting T lymphocytes. Both 
CD2 and CD3  activation pathways cooperate with CD28 
as a consequence of CD28  binding its  natural ligand B7. 
With respect to induction of cytotoxicity, the CD45RO + 
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Figure 11.  B7-independent anti-CD3-redirected cytotoxicity mediated 
by T cell clones. TCR-~//~*  (Jp28a.6, 1360b.I, and 1320.3) and TCR- 
3~/di*  (1375b2.22) T cell clones were incubated with slCr-labeled B7 + 
P815 (I) or P815 (i) in the presence or absence of anti-CD3 mAb, as 
indicated.  E/T ratio was 10:1. 
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used for these experiments. Moreover, cytotoxicity was only 
observed using the B7 + P815 transfectant and not with the 
parental P815 cells.  Since in vitro cultured CTL,  as well as 
the  presumably in  vivo activated  CD56 +  T  cells mediate 
redirected lysis against parental P815, it seems likely that the 
CD28/B7 interaction is necessary only for costimulation of 
small, resting T cells and is no longer required after activa- 
tion. Consistent with this concept, we have previously demon- 
strated that TCR-qr//~ + T  lymphocytes that mediate potent 
anti-CD3-redirected cytotoxicity downregulate CD28 expres- 
sion after stimulation with Ib2 (37). Moreover, the subset 
of CD28-  peripheral  blood T  cells  that  coexpress CDllb 
in vivo are predominantly granular,  low buoyant density T 
cells that  may represent  activated T  cells  that  have under- 
gone clonal expansion (38, 39). Therefore, the CD28/B7 in- 
teraction may be most critical in the early generation  of a 
ceU-mediated immune response,  consistent with a possible 
role of CD28/B7 in the stimulation of immature thymocytes 
(40, 41). The existence of functional cytolytic T cells in the 
small,  resting  T  cell  population  may be  advantageous  in 
facilitating  rapid responses to immune  challenge. 
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